New Ovarian Cancer Study Is Released

Many important studies were presented last week at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Los Angeles, CA.  Among them were two studies that were covered in multiple media outlets, including the New York Times (click here to read the article).  The first study looked at more than 13,000 women with ovarian cancer and found that women are 30 percent less likely to die of ovarian cancer if they have guideline-recommended treatment.  Yet, nearly two-thirds of those women do not receive it.  Guidelines for ovarian cancer specify types of surgical procedures and chemotherapy, often the need for debulking surgery prior to chemotherapy.  The study found that surgeons who were more experienced in gynecologic oncology surgery, and hospitals that treated more women with ovarian cancer, were more likely to follow the guidelines, which translated to better outcomes for their patients.  The second study looked at the method of delivery of chemotherapy to patients.  Intraperitoneal (IP) chemotherapy, where chemotherapy drugs are pumped directly into the abdomen, utilizes the same chemotherapy agents often administered intravenously. While IP chemotherapy is more toxic, and logistically more complicated than IV chemotherapy, there is clearly a benefit in terms of survival rate.   

For you, the patient, these studies underscore the importance of making sure that you act as your own advocate by asking to be treated by a physician with ovarian cancer expertise and experience who practices according to available guidelines.  For ovarian cancer information and support, please call Sharsheret at 866.474.2774 or e-mail info@sharsheret.org

Ethan Wasserman, MD
Sharsheret Medical Advisory Board Member

THE VIEWS EXPRESSED ON THE BLOG ARE THOSE OF THE INDIVIDUAL USERS AND NOT NECESSARILY THE VIEWS OF SHARSHERET. ALTHOUGH SHARSHERET WILL BE MODERATING ALL MESSAGES POSTED TO THE BLOG, WE DO NOT CONFIRM OR WARRANT THE USEFULNESS, ACCURACY, OR COMPLETENESS OF ANY MESSAGES AND ARE NOT RESPONSIBLE FOR ANY DAMAGE OR LOSS RELATED TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION. SHARSHERET DOES NOT MAKE ANY EXPRESSED OR IMPLIED WARRANTIES WITH REGARD TO INFORMATION OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTIES OF TITLE OR NON-INFRINGEMENT. IN NO EVENT SHALL THE PROVIDERS BE LIABLE TO YOU OR A THIRD PARTY FOR ANY ACTION, OR FAILURE TO ACT BASED ON RELIANCE ON THE CONTENT POSTED ON THE BLOG. ALL INFORMATION IS PROVIDED WITHOUT ANY WARRANTY OF ANY KIND.

ovarian cancer

Dr. Wasserman, I am so happy to see that although you have changed your office you have not left this field.  You are both knowledgeable and caring and a doctor those of us with the BRCA gene need in our corner.  Thank you for all you do and for keeping us informed.

 

 

 

 

 

Post new comment

The content of this field is kept private and will not be shown publicly.
Image CAPTCHA
Enter the characters shown in the image.
By submitting this form, you accept the Mollom privacy policy.
Placeholder for AddThis